A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

By Goss G.   Hirte H.   Miller W.   Lorimer I.   Stewart D.   Batist G.   Parolin D.   Hanna P.   Stafford S.   Friedmann J.   Walsh W.   Mathews S.   Douglas L.   Seymour L.  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 147-155

Springer Publishing Company

Access to resources Recommend Favorite

SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

By Wong R.   Baetz T.   Krahn M.   Biagi J.   Wainman N.   Eisenhauer E.  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 347-351

Springer Publishing Company

Access to resources Recommend Favorite

Concordance between Rats and Mice in Bioassays for Carcinogenesis

By Freedman D.A.   Gold L.S.   Lin T.H.  

Regulatory Toxicology and Pharmacology, Vol. 23, Iss. 3, 1996-06 ,pp. : 225-232

Academic Press

Access to resources Recommend Favorite

Hormesis at the National Toxicology Program (NTP): Evidence of Hormetic Dose Responses in NTP Dose-Range Studies

By Calabrese Edward J.    

Nonlinearity in Biology, Vol. 1, Iss. 4, 2003-10 ,pp. : 455-467

Taylor & Francis Ltd

Access to resources Recommend Favorite

Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: A National Cancer Institute of Canada Clinical Trials Group investigational new drug study

By Winquist Eric   Knox Jennifer   Ayoub Jean-Pierre   Wood Lori   Wainman Nancy   Reid Gregory   Pearce Laura   Shah Ajit   Eisenhauer Elizabeth  

Investigational New Drugs, Vol. 24, Iss. 2, 2006-03 ,pp. : 159-167

Springer Publishing Company

Access to resources Recommend Favorite